Important note: Information in this article was accurate in May 2009. The state of the art may have changed since the publication date.
Etravirine dose selection in children aged 6 to 17
HIV Treat Bull - 2009 May-Jun;10(5/6): 20
Polly Clayden, HIV i-Base
Chistoph Konigs and coworkers from paediatric centres in Europe performed a dose finding study of etravirine (ETR) in treatment experienced children >6 years and weighing >20kg.
This was a phase 1, open label trial in two sequential stages. 21 HIV-positive children on stable lopinavir/r-based ART with viral load <50 copies/mL were enrolled in each stage. Children in stage I received 4mg/kg ETR bid following a meal (included in HTB reports from CROI last year). Children in Stage II received 5.2mg/kg ETR bid following a meal. ETR was added to background regimen for 7 days. After the morning dose on day 8 the investigators performed a 12 hour PK evaluation. 100mg and proportional 25mg tablets were used in this study. PK for 19 and 20 children were available in stages I and II, respectively.
The investigators reported the mean (SD) Cmax in stage I and II, respectively, was 495 (453) and 757 (680) ng/mL; Cmin was 184 (151) and 294 (278) ng/mL; and AUC12h was 4050 (3602) and 6141 (5586) ng•h/mL.
When they compared PK parameters to those reported in adult trials (n=575), population derived Cmin was 393 [391] ng/mL and AUC12h was 5506 [4710] ng•h/mL, they found the levels achieved in children participating in stage II with the higher dose to be more appropriate.
All children had a viral load <50 copies/mL on day 8. The majority of side effects were grade 1 or 2, most commonly rhinitis or headache. Two children in stage 1 had a mild to moderate rash on day 8. No child discontinued treatment due to toxicity.
The target dose of ETR in children 6-17 years was selected as 5.2mg/kg bid, which provides comparable exposure to the adult dose of 200mg bid.
Further studies in children are ongoing or planned.
Comment
Tibotec intend to market the 25-mg tablet for children (and adults who have difficulty swallowing the 100-mg tablets) once they have the initial paediatric indication.
Ref: Konigs et al. Pharmacokinetics and dose selection of etravirine in HIV-infected children between 6 and 17 years inclusive. Conf Retroviruses Opportunistic Infect 2009 Feb 8-11;16: Poster abstract 879.
2009-05-10
IB2009-05-20
©2009. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.